fbpx

Day

November 11, 2014
Proceeds to enable clinical Phase 2 Proof-of-Concept studies for two lead compounds - a histamine H4 receptor antagonist for atopic dermatitis and a topical cPLA2 inhibitor for psoriasis

News

Ancient DNA throws a ‘scientific hand grenade’ into the discussion about the arrival of humans in North America
23. July 2020
Danish researchers map key disease mechanism – and describe a completely new protein
20. July 2020
Five young medical students to conduct research in the US
9. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge